Andrew John Hugh MacIntyre Sims is CFO at PLUS THERAPEUTICS, INC. (PSTV). They have made 8 open-market trades across 1 company since 2021, most recently 2026-10-01.
CIK 0001802687
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
8 open-market purchases totalling $43K since 2021, never a sale. Across 8 scored buys the stock is down 35.2% at ninety days, and 34.7 points behind the S&P over the same stretch.
8 scored purchases · one row per filing · discretionary only
| Ticker | Shares | Value |
|---|---|---|
| PSTV | 8,489 | $33K |
| CNSY | 11,474 | — |
| Total | $33K |
Shares reported on the most recent Form 4, priced at the 2026-10-01 close. 1 holding could not be priced and is excluded from the total.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 25% | 25% | 0% |
| Avg Move | -7.1% | -8.1% | -35.2% |
| Alpha | -7.1% | -9.9% | -34.7% |
| Scored | 8 | 8 | 8 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| PSTV | BUY | 2025-11-04 | 2025-11-05 | $0.51 | $10K | -18.1% | +12.1% | -58.5% |
| PSTV | BUY | 2024-09-10 | 2024-09-11 | $1.27 | $5K | +18.0% | +1.7% | -3.2% |
| PSTV | BUY | 2024-05-08 | 2024-05-10 | $2.04 | $10K | -5.2% | -3.9% | -32.6% |
| PSTV | BUY | 2022-04-26 | 2022-04-27 | $0.67 | $2K | -31.7% | -19.0% | -28.9% |
| PSTV | BUY | 2022-03-01 | 2022-03-03 | $1.10 | $2K | -10.3% | -4.7% | -48.6% |
| PSTV | BUY | 2021-11-02 | 2021-11-04 | $1.86 | $2K | -10.3% | -33.2% | -46.7% |
| PSTV | BUY | 2021-10-26 | 2021-10-27 | $1.67 | $3K | +5.2% | -13.3% | -49.9% |
| PSTV | BUY | 2021-07-27 | 2021-07-29 | $1.98 | $8K | -4.6% | -4.6% | -12.8% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.